357 related articles for article (PubMed ID: 33239409)
1. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1715-1727. PubMed ID: 33239409
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Ito S; Shikata K; Nangaku M; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2019 Aug; 14(8):1161-1172. PubMed ID: 31248950
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study.
Itoh H; Ito S; Rakugi H; Okuda Y; Nishioka S
Hypertens Res; 2019 Oct; 42(10):1572-1581. PubMed ID: 31239535
[TBL] [Abstract][Full Text] [Related]
5. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
Arai K; Morikawa Y; Ubukata N; Sugimoto K
Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
[TBL] [Abstract][Full Text] [Related]
6. Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies.
Shikata K; Ito S; Kashihara N; Nangaku M; Wada T; Okuda Y; Sawanobori T; Sugimoto K
J Diabetes Investig; 2022 Jul; 13(7):1190-1202. PubMed ID: 35199478
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria: A Randomized, Controlled Trial.
Ito S; Kagawa T; Saiki T; Shimizu K; Kuroda S; Sano Y; Umeda Y
Clin J Am Soc Nephrol; 2019 Mar; 14(3):354-363. PubMed ID: 30755452
[TBL] [Abstract][Full Text] [Related]
8. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
[TBL] [Abstract][Full Text] [Related]
9. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.
Ito S; Itoh H; Rakugi H; Okuda Y; Yamakawa S
J Hum Hypertens; 2019 Jul; 33(7):542-551. PubMed ID: 31113987
[TBL] [Abstract][Full Text] [Related]
11. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
12. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y;
J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025
[TBL] [Abstract][Full Text] [Related]
14. Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.
August P; Hardison RM; Hage FG; Marroquin OC; McGill JB; Rosenberg Y; Steffes M; Wall BM; Molitch M;
Clin J Am Soc Nephrol; 2014 Jan; 9(1):64-71. PubMed ID: 24178969
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction.
Ito S; Itoh H; Rakugi H; Okuda Y; Iijima S
Hypertens Res; 2021 May; 44(5):489-497. PubMed ID: 33323991
[TBL] [Abstract][Full Text] [Related]
16. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study.
Uchida HA; Nakajima H; Hashimoto M; Nakamura A; Nunoue T; Murakami K; Hosoya T; Komoto K; Taguchi T; Akasaka T; Shiosakai K; Sugimoto K; Wada J;
Adv Ther; 2022 Nov; 39(11):5158-5175. PubMed ID: 36070133
[TBL] [Abstract][Full Text] [Related]
18. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
[TBL] [Abstract][Full Text] [Related]
19. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.
Rakugi H; Ito S; Itoh H; Okuda Y; Yamakawa S
Hypertens Res; 2019 Dec; 42(12):1932-1941. PubMed ID: 31554937
[TBL] [Abstract][Full Text] [Related]
20. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
Li L; Guan Y; Kobori H; Morishita A; Kobara H; Masaki T; Nakano D; Nishiyama A
Hypertens Res; 2019 Jun; 42(6):769-778. PubMed ID: 30587856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
